Global active pharmaceutical ingredients (API) market will reach $293.5 billion by 2026, growing by 7.2% annually over 2020-2026 owing to the rising need for medicine and pharmaceutical agents amid the COVID-19 pandemic.

Highlighted with 91 tables and 99 figures, this 190-page report “Global Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure 

• Growth Drivers 

• Restraints and Challenges

• Emerging Product Trends & Market Opportunities

• Porter’s Fiver Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Region. 

Based on Synthesis, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section. 

Synthetic API

• Branded Synthetic API

• Generic Synthetic API

Biotech API by Drug Type:

• Monoclonal Antibodies

• Recombinant Proteins

• Vaccines

• Other Biotech APIs

Biotech API by Customer Base:

•   Innovative Biologic API

•   Generic Biosimilar API

Biotech API by Expression Technology:

• Mammalian Expression

• Microbial Expression

• Yeast Expression

• Insect Expression

• Other Expression Technologies

HPAPI

•   Branded HPAPI

•   Generic HPAPI

Based on Manufacturing Process, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section. 

Captive Manufacturing

• Branded Captive API

• Generic Captive API

Merchant Manufacturing by Drug Type:

• Branded Merchant API

• Generic Merchant API

Merchant Manufacturing by Drug Synthesis:

• Merchant Synthetic API

• Merchant Biotech API

Based on Therapeutic Application, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section. 

• Infectious Diseases

• Oncology

• Ophthalmology 

• Cardiovascular Disorders

• Central Nervous System

• Pulmonary Disorders

• Orthopedics

• Other Applications

Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section. 

• Branded Prescription Drugs

• Generic Prescription Drugs

• OTC Drugs

Geographically, the following regions together with the listed national/local markets are fully investigated:

• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

• North America (U.S., Canada, and Mexico)

• South America (Brazil, Chile, Argentina, Rest of South America)

• RoW (Saudi Arabia, UAE, South Africa)

For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of all regional markets by country and split of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in global API market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request): 

AbbVie Inc. 

Astrazeneca 

Aurobindo Pharma Ltd. 

Bayer Healthcare 

Bioniche Animal Health 

Boehringer Ingelheim 

Bristol-Myers Squibb 

Ceva Animal Health, Inc. 

Elanco Animal Health 

Eli Lilly and Company 

F. Hoffmann-La Roche 

Glaxosmithkline PLC 

Heska Co. 

Lonza Group 

Merck & Co., Inc. 

Novartis International AG 

Pfizer, Inc. 

Ranbaxy Laboratories 

Sanofi 

Sun Pharmaceutical Industries Ltd. 

 (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)